Kinsale Capital Is Down Bad -- Here's Why I'm Still Holding

Video (published Mar 14, 2026; uses morning prices of Mar 11, 2026) states Kinsale Capital (NYSE: KNSL) has underperformed recently due to competitive headwinds, but the presenter remains a long‑term holder. The Motley Fool discloses that Matt Frankel and The Motley Fool hold positions and recommend Kinsale, while Stock Advisor's current top‑10 list did not include the stock. Commentary is opinionated and promotional for Stock Advisor rather than new company-specific financial data.

Analysis

The most important competitive dynamic is scale-in-market and capital flexibility: smaller specialty underwriters face margin pressure when brokers reallocate flow toward carriers that can (a) offer lower rates and (b) absorb volatility on balance sheet. That accelerates a two-track market where capital-rich reinsurers or public carriers with diversified float can selectively price for profit, forcing mid-sized specialists to either raise prices faster (losing premium volume) or accept compressed loss-adjusted returns.

Near-term catalysts are discrete and measurable: quarterly reserve development, spring–summer reinsurance renewals, and the next set of commercial-rate filings. A 200–300bps move in combined ratio expectations across the next 6–12 months will change free cash flow conversion and either justify a multiple re-rating or force capital actions (dividends/buybacks) — conversely, a single large CAT or adverse reserve run-off could wipe out a year of expected earnings and re-price equity by 30%+ within days.

The consensus underestimates management optionality around capital allocation: constrained organic growth often pushes specialty managers into buybacks or incremental risk-taking in investment allocation to hit ROE targets, which creates convex downside if equities correct. That makes structured exposure preferable to outright equity exposure — you want to own upside to a re-rating while explicitly limiting tail losses from underwriting or investment shocks.

Key Decisions for Investors

• Tactical long KNSL equity (size 2–4% portfolio) with protective puts: buy KNSL stock for a 9–12 month horizon and simultaneously buy 6–9 month 10–15% OTM puts to cap downside. Risk/Reward: asymmetric — ~40–60% upside if combined ratio improves by ~200bps and rates normalize vs limited ~15–20% financed downside (net of put cost).
• Relative-value pair: long KNSL / short RE (Everest Re) for 6–12 months — size 1–2% net market exposure. Thesis: if specialty rates firm and retail-focused carriers reallocate premium, KNSL re-rating will outpace large reinsurers; reward if KNSL EPS inflects, risk if a major CAT tightens reinsurance margins globally.
• Event hedge / short catalyst: buy 3–6 month KNSL puts (deeper OTM) sized to cover potential reserve/CAT shock scenarios (target protection to cover 20–30% downside). This is a low-cost insurance trade to deploy before spring reinsurance renewals and earnings.
• Macro hedge via NVDA calls (complementary trade): buy 6–12 month NVDA calls (small position) as a positive-alpha hedge for portfolio liquidity and to capture the asymmetric upside in equities that could improve insurer investment returns and surplus — expected payoff if tech-led equity rally lifts insurer mark-to-market and reduces need for risky capital moves.